Bilateral Anterior Uveitis Associated with Nivolumab Therapy

Ocular Immunology and Inflammation

Volumn 26, Issue 2, 2018, Pages 283-285

  Karlin, Justin ^a   Gentzler, Ryan ^b   Golen, Jeffrey ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPENTOLATE; DIPEPTIDYL CARBOXYPEPTIDASE; DOCETAXEL; GEMCITABINE; LYSOZYME; NIVOLUMAB; PEMETREXED; PREDNISOLONE ACETATE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADRENAL METASTASIS; AGED; BEST CORRECTED VISUAL ACUITY; BILATERAL ANTERIOR UVEITIS; BLURRED VISION; CANCER CHEMOTHERAPY; CASE REPORT; CATARACT; CLINICAL ARTICLE; ENZYME BLOOD LEVEL; EYE REDNESS; FEMALE; HUMAN; IRIDOCYCLITIS; LETTER; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; MULTIPLE CYCLE TREATMENT; OPTICAL COHERENCE TOMOGRAPHY; PRESBYOPIA; SMALL CELL LUNG CANCER; CHEMICALLY INDUCED; LUNG TUMOR; NON SMALL CELL LUNG CANCER;

AGED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; NIVOLUMAB; UVEITIS, ANTERIOR;

EID: 84986218448     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.1080/09273948.2016.1215473     Document Type: Letter

References (13)

1. Jabs DA, Nussenblatt RB, Rosenbaum JT,; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516.
2. United States Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v. 4.03, June 14, 2010. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed August 8, 2016.
3. London NJ, Garg SJ, Moorthy RS, et al. Drug-induced uveitis. J Ophthalmic Inflamm Infect. 2013;3:43.
4. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245.
5. Keir M, Butte M, Freeman F, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
6. D’Incecco A, Andreozzi M, Ludovini V, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer. 2015;112:95–102.
7. Borghaei H, Brahmer J., Nivolumab in nonsquamous non-small-cell lung cancer. N Engl J Med. 2016;374:493–494.
8. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial. Lancet. 2016;387:1540–1550.
9. Zhou R, Caspi RR., Ocular immune privilege. F1000 Biol Rep. 2010;2:ii.
10. Sugita S, Usui Y, Horie S, et al. T-cell suppression by programmed cell death 1 ligand 1 on retinal pigment epithelium during inflammatory conditions. Invest Ophthalmol Vis Sci. 2009;50:2862–2870.
11. Lee DJ, Taylor AW., Recovery from experimental autoimmune uveitis promotes induction of antiuveitic inducible Tregs. J Leukoc Biol. 2015;97:1101–1109.
12. de Velasco G, Bermas B, Choueiri TK., Auto-immune arthropathy and uveitis as complications from PD-1 inhibitor. Arthritis Rheumatol. 2016;68:556–557.
13. Abu Samra K, Valdes-Navarro M, Lee S., A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur J Ophthalmol. 2016;26:e46–e48.